The third aspect of interest to future research is examining whether cytokines for T cell expansion (such as recombinant IL-7 or IL-15) restore lymphopenia and improve treatment responses to CDK4/6 inhibitors, because CDK4/6 inhibitor-related lymphopenia was associated with poor outcomes in our study. Here, CDK4 is linked to lymphopenia.